AVEO Aveo Pharmaceuticals Inc

Price (delayed)

$7.74

Market cap

$267.91M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.03

Enterprise value

$236.18M

AVEO Pharmaceuticals Inc. is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO's strategy is to focus its resources toward the development ...

Highlights
The company's EPS rose by 48% YoY and by 13% QoQ
Aveo Pharmaceuticals's net income has increased by 35% YoY and by 13% QoQ
The quick ratio has plunged by 52% YoY and by 35% from the previous quarter
AVEO's equity is down by 49% YoY and by 17% QoQ

Key stats

What are the main financial stats of AVEO
Market
Shares outstanding
34.61M
Market cap
$267.91M
Enterprise value
$236.18M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.72
Price to sales (P/S)
3.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.99
Earnings
Revenue
$79.04M
EBIT
-$31.48M
EBITDA
-$31.41M
Free cash flow
-$30.93M
Per share
EPS
-$1.03
Free cash flow per share
-$0.9
Book value per share
$0.89
Revenue per share
$2.29
TBVPS
$2.84
Balance sheet
Total assets
$98.11M
Total liabilities
$67.52M
Debt
$38.43M
Equity
$30.59M
Working capital
$66.09M
Liquidity
Debt to equity
1.26
Current ratio
3.1
Quick ratio
2.93
Net debt/EBITDA
1.01
Margins
EBITDA margin
-39.7%
Gross margin
88.3%
Net margin
-45.7%
Operating margin
-39.9%
Efficiency
Return on assets
-35.2%
Return on equity
-87.8%
Return on invested capital
-69%
Return on capital employed
-47.3%
Return on sales
-39.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AVEO stock price

How has the Aveo Pharmaceuticals stock price performed over time
Intraday
-2.4%
1 week
-3.25%
1 month
11.69%
1 year
34.61%
YTD
65.03%
QTD
17.99%

Financial performance

How have Aveo Pharmaceuticals's revenue and profit performed over time
Revenue
$79.04M
Gross profit
$69.77M
Operating income
-$31.54M
Net income
-$36.14M
Gross margin
88.3%
Net margin
-45.7%
The company's operating margin has surged by 90% YoY and by 38% QoQ
AVEO's net margin has surged by 89% year-on-year and by 32% since the previous quarter
The company's operating income rose by 43% YoY and by 20% QoQ
Aveo Pharmaceuticals's net income has increased by 35% YoY and by 13% QoQ

Growth

What is Aveo Pharmaceuticals's growth rate over time

Valuation

What is Aveo Pharmaceuticals stock price valuation
P/E
N/A
P/B
8.72
P/S
3.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.99
The company's EPS rose by 48% YoY and by 13% QoQ
The P/B is 71% higher than the last 4 quarters average of 5.1
AVEO's equity is down by 49% YoY and by 17% QoQ
The price to sales (P/S) is 86% lower than the 5-year quarterly average of 24.4 and 25% lower than the last 4 quarters average of 4.5
The revenue has increased by 29% from the previous quarter

Efficiency

How efficient is Aveo Pharmaceuticals business performance
The company's return on sales has surged by 90% YoY and by 34% QoQ
The return on invested capital has surged by 65% year-on-year and by 5% since the previous quarter
AVEO's ROA is up by 40% YoY and by 10% QoQ
The ROE has grown by 18% YoY but it has contracted by 2.9% from the previous quarter

Dividends

What is AVEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVEO.

Financial health

How did Aveo Pharmaceuticals financials performed over time
The total assets is 45% greater than the total liabilities
The quick ratio has plunged by 52% YoY and by 35% from the previous quarter
The current ratio has dropped by 51% year-on-year and by 36% since the previous quarter
AVEO's debt is 26% greater than its equity
AVEO's debt to equity has surged by 129% year-on-year and by 22% since the previous quarter
AVEO's equity is down by 49% YoY and by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.